Monday, July 28, 2008

Certain Antipsychotics Increase Metabolic, Cardiovascular Risk Factors

Some atypical antipsychotics may be more likely than others to cause metabolic and cardiovascular side effects, according to a study published in the August 2008 issue of Schizophrenia Research.

The study was based on recent data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.

Jonathan Meyer, MD, University of California at San Diego, San Diego, California, and colleagues compared baseline data with those collected 3 months later from 281 CATIE participants who were randomly assigned to treatment with 1 of 5 antipsychotics -- olanzapine, risperidone, ziprasidone, quetiapine, or perphenazine.

READ MORE @ DOCTOR'S GUIDE